GAMMA Investing LLC Acquires New Stake in Moderna, Inc. (NASDAQ:MRNA)

GAMMA Investing LLC acquired a new stake in Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 2,172 shares of the company’s stock, valued at approximately $219,000.

Several other hedge funds have also recently added to or reduced their stakes in MRNA. The Manufacturers Life Insurance Company raised its stake in Moderna by 77.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock valued at $400,367,000 after purchasing an additional 1,690,341 shares during the last quarter. Invesco Ltd. raised its stake in Moderna by 19.8% in the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock valued at $322,887,000 after purchasing an additional 517,683 shares during the last quarter. Wellington Management Group LLP raised its stake in Moderna by 9.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company’s stock valued at $579,572,000 after purchasing an additional 476,201 shares during the last quarter. Bamco Inc. NY raised its stake in Moderna by 4,863.6% in the 3rd quarter. Bamco Inc. NY now owns 426,869 shares of the company’s stock valued at $44,091,000 after purchasing an additional 418,269 shares during the last quarter. Finally, abrdn plc grew its holdings in Moderna by 477.5% in the 4th quarter. abrdn plc now owns 483,574 shares of the company’s stock valued at $48,091,000 after buying an additional 399,843 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Stock Performance

Shares of Moderna stock opened at $106.18 on Friday. The business has a 50-day moving average of $102.15 and a 200 day moving average of $93.73. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $142.79. The stock has a market capitalization of $40.65 billion, a price-to-earnings ratio of -8.56 and a beta of 1.62. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. The company had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. Moderna’s revenue for the quarter was down 44.9% compared to the same quarter last year. During the same quarter last year, the company earned $3.61 EPS. As a group, sell-side analysts forecast that Moderna, Inc. will post -7.51 earnings per share for the current year.

Insider Buying and Selling at Moderna

In other news, President Stephen Hoge sold 2,388 shares of the firm’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the sale, the president now owns 1,515,898 shares of the company’s stock, valued at approximately $143,358,473.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Moderna news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $103.38, for a total transaction of $1,550,700.00. Following the transaction, the director now owns 2,056,931 shares of the company’s stock, valued at $212,645,526.78. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, President Stephen Hoge sold 2,388 shares of Moderna stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the transaction, the president now owns 1,515,898 shares in the company, valued at $143,358,473.86. The disclosure for this sale can be found here. Insiders have sold 109,954 shares of company stock valued at $11,533,976 in the last quarter. Corporate insiders own 15.70% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on MRNA shares. Royal Bank of Canada restated an “outperform” rating and issued a $125.00 target price on shares of Moderna in a report on Thursday, March 28th. William Blair restated a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Canaccord Genuity Group upped their target price on Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a report on Friday, February 23rd. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Thursday, April 11th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $125.00 price target on shares of Moderna in a report on Tuesday, April 9th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $126.49.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.